Rule 26 Information

One of the UK's leading commercial stage pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses and our own research activities.  The strategy is to:

  • Build a profitable and cash generative business
  • Develop and commercialise low development-risk late-stage products for unmet medical needs in the US
  • Partner all of our NCE drug candidates
  • Leverage our structure- and fragment-based drug discovery expertise via collaborations with leading pharmaceutical companies

 

Title PDF
Interim Results 31 Dec 2016
2015/16 Report and Accounts
Circular for Placing and Notice of General Meeting 
Interim Results 31 Dec 2015
2014/15 Report and Accounts
2014 H2 Interim Results
2014 Interim Results
2013 Annual Report
2013 Interim Results
2012 Annual Report
Vernalis' articles of association
2012 Interim Results
Placing and Open Offer February 2012

 

Number of AIM securities in issue: 526,352,521
Percentage of AIM securities not in public hands: 87.59%

 

Identity and percentage holdings of it's significant shareholders Number of shares held % of issued shares
Invesco Asset Management 194,417,167 36.94
Woodford Investment Management 157,876,138 29.99
GAM London Ltd 47,861,787 9.09
Legal & General Investment Management 29,872,619 5.68
Aviva Investors 26,056,441 4.95

 

There are no restrictions on the transfer of Vernalis AIM Securities

Vernalis is subject to the UK City Code on Takeovers and Mergers

Vernalis plc is incorporated in England and Wales and its main countries of operation are the UK and US

Details of director's biographies are listed on the About Us / Our People / Board of Directors page and by clicking here

 

Information last updated January 2017

Note: To view PDF files, you will need the Adobe Acrobat Reader. This can be downloaded free of charge from the Adobe website.

Latest News

Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership

Vernalis plc and Servier are pleased to announce that they reinforce their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch